Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Fondation Imagine is currently active in the Biotechnology & Pharmaceuticals technology area. The portfolio contains 3 pending office actions, which are distributed across 3 distinct examiners. This arrangement indicates that the company's current prosecution efforts are spread across multiple individuals, requiring a strategy that accounts for different examiner perspectives. The involvement of 3 distinct art units further suggests that the technical subject matter is being reviewed by various specialized groups within the patent office.
The busiest examiner for this portfolio is COUNTS, GARY W, who is responsible for 1 busiest_examiner_pending office action. Because this examiner only manages a portion of the total pending workload, the applicant must maintain separate dialogues with each of the examiners involved. This lack of concentration means that the outcomes in one case may not necessarily influence the progression of others in the biotechnology and pharmaceutical sector.
Practitioners should observe that the 3 pending office actions are handled by an equal number of examiners and art units. This structure prevents a single examiner from becoming a bottleneck for the entire portfolio. However, it also requires the applicant to tailor their arguments to the specific requirements of COUNTS, GARY W and the other officials overseeing the 1 pending action assigned to them.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COUNTS, GARY W | 1 | 58.9% | +29.7% |
| LIPPOLIS, ALEXANDRA ROSE | 1 | 47.2% | +63.6% |
| SULLIVAN, STEPHANIE LAUREN | 1 | 57.1% | +38.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998603 | BASE EDITING APPROACHES FOR THE TREATMENT OF BETAHEMOGLOBINOPATHIES | LIPPOLIS, ALEXANDRA ROSE | 4d overdue |
| 17274966 | METHODS FOR INCREASING FETAL HEMOGLOBIN CONTENT IN EUKARYOTIC CELLS AND USES THEREOF FOR THE TREATMENT OF HEMOGLOBINOPATHIES | SULLIVAN, STEPHANIE LAUREN | 12d |
| 18017249 | Type 1 IFN Assays and Methods of Diagnosis for Susceptibility to and Treatment of Viral Disease and Viral Vaccines, Including Covid -19 | COUNTS, GARY W | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998603 | BASE EDITING APPROACHES FOR THE TREATMENT OF BETAHEMOGLOBINOPATHIES | LIPPOLIS, ALEXANDRA ROSE | 4d overdue |
| 17274966 | METHODS FOR INCREASING FETAL HEMOGLOBIN CONTENT IN EUKARYOTIC CELLS AND USES THEREOF FOR THE TREATMENT OF HEMOGLOBINOPATHIES | SULLIVAN, STEPHANIE LAUREN | 12d |
| 18017249 | Type 1 IFN Assays and Methods of Diagnosis for Susceptibility to and Treatment of Viral Disease and Viral Vaccines, Including Covid -19 | COUNTS, GARY W | — |
| Art Unit | Apps |
|---|---|
| 1678 | 1 |
| 1637 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18017249 | Type 1 IFN Assays and Methods of Diagnosis for Susceptibility to and Treatment of Viral Disease and Viral Vaccines, Including Covid -19 | COUNTS, GARY W | 1678 | §101§103§112 | Non-Final OA | — | Pending | Jan 20, 2023 |
| 17998603 | BASE EDITING APPROACHES FOR THE TREATMENT OF BETAHEMOGLOBINOPATHIES | LIPPOLIS, ALEXANDRA ROSE | 1637 | §103§112 | Non-Final OA | 4d overdue | Pending | Nov 11, 2022 |
| 17274966 | METHODS FOR INCREASING FETAL HEMOGLOBIN CONTENT IN EUKARYOTIC CELLS AND USES THEREOF FOR THE TREATMENT OF HEMOGLOBINOPATHIES | SULLIVAN, STEPHANIE LAUREN | 1635 | §103§112 | Non-Final OA | 12d | Pending | Mar 10, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFondation Imagine has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Gary W Counts has the most, with 1 of Fondation Imagine's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
